Pyrrolidine dithiocarbamate and zinc inhibit proteasome-dependent proteolysis

Experimental Cell Research

Volumn 298, Issue 1, 2004, Pages 229-238

  Kim, Insook ^a   Kim, Chul Hoon ^a   Kim, Joo Hee ^a   Lee, Jinu ^a   Choi, Jun Jeong ^a   Chen, Zheng Ai ^a   Lee, Min Goo ^a   Chung, Kwang Chul ^a   Hsu, Chung Y ^b   Ahn, Young Soo ^a  

^a Yonsei University College of Medicine   (South Korea)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

p21; p53; Proteasomes; Zinc; Synuclein

Indexed keywords

ALPHA SYNUCLEIN; BIOLOGICAL MARKER; HYBRID PROTEIN; POLYUBIQUITIN; PROTEASOME; PROTEIN P21; PROTEIN P53; PYRROLIDINE DITHIOCARBAMATE; UBIQUITIN; ZINC;

ARTICLE; CELL INCLUSION; CENTROSOME; CONTROLLED STUDY; ENZYME INHIBITION; ENZYME SUBSTRATE; HELA CELL; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN DEGRADATION; UBIQUITINATION; WESTERN BLOTTING;

EID: 3042745312     PISSN: 00144827     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.yexcr.2004.04.017     Document Type: Article

References (59)

1. Hayes W.J. Pesticides Studied in Man. 1982;Williams and Wilkins, Baltimore
2. Thorn G.D., Ludwig R.A. The Dithiocarbamates and Related Compounds. 1962;Elsevier, Amsterdam
3. Reisinger E.C., Kern P., Ernst M., Bock P., Flad H.D., Dietrich M. Inhibition of HIV progression by dithiocarb. German DTC study group. Lancet. 335:1990;679-682
4. Gandara D.R., Perez E.A., Weibe V., De Gregorio M.W. Cisplatin chemoprotection and rescue: pharmacologic modulation of toxicity. Semin. Oncol. 18:1991;49-55
5. WAF1/CIP1 via C/EBPβ Nat. Med. 3:1997;1233-1241
6. Bach S.P., Chinery R., O'Dwyer S.T., Potten C.S., Coffey R.J., Watson A.J. Pyrrolidinedithiocarbamate increases the therapeutic index of 5-fluorouracil in a mouse model. Gastroenterology. 118:2002;81-89
7. Somers P.K., Medford R.M., Saxena U. Dithiocarbamates: effects on lipid hydroperoxides and vascular inflammatory gene expression. Free Radic. Biol. Med. 28:2000;1532-1537
8. Schreck R., Meier B., Männel D.N., Dröge W., Baeuerle P.A. Dithiocarbamates as potent inhibitors of nuclear factor κB activation in intact cells. J. Exp. Med. 175:1992;1181-1194
9. Kim C.H., Kim J.H., Hsu C.Y., Ahn Y.S. Zinc is required in pyrrolidine dithiocarbamate inhibition of NF-κB. FEBS Lett. 449:1999;28-32
10. Kim C.H., Kim J.H., Lee J., Hsu C.Y., Ahn Y.S. Thiol antioxidant reversal of pyrrolidine dithiocarbamate-induced reciprocal regulation of AP-1 and NF-κB. Biol. Chem. 384:2002;143-150
11. Kim C.H., Kim J.H., Lee J., Ahn Y.S. Zinc-induced NF-κB inhibition can be modulated by changes in intracellular metallothionein level. Toxicol. Appl. Pharmacol. 190:2003;189-196
12. Kim C.H., Kim J.H., Moon S.J., Hsu C.Y., Seo J.T., Ahn Y.S. Biphasic effects of dithiocarbamates on the activity of nuclear factor-κB. Eur. J. Pharmacol. 392:2000;133-136
13. Beyersmann D., Haase H. Functions of zinc in signaling, proliferation and differentiation of mammalian cells. BioMetals. 14:2001;331-341
14. Zalewski P.D., Millard S.H., Forbes I.J., Kapaniris O., Slavotinek A., Betts W.H., Ward A.D., Lincoln S.F., Mahadevan I. Video image analysis of labile zinc in viable pancreatic islet cells using a specific fluorescent probe for zinc. J. Histochem. Cytochem. 42:1994;877-884
15. Kim B.J., Kim Y.H., Kim S., Kim J.W., Koh J.Y., Oh S.H., Lee M.K., Kim K.W., Lee M.S. Zinc as a paracrine effector in pancreatic islet cell death. Diabetes. 49:2000;367-372
16. Iguchi K., Hamatake M., Ishida R., Usami Y., Adachi T., Yamamoto H., Koshida K., Uchibayashi T., Hirano K. Induction of necrosis by zinc in prostate carcinoma cells and identification of proteins increased in association with this induction. Eur. J. Biochem. 253:1998;766-770
17. Uzzo R.G., Leavis P., Hatch W., Gabai V.L., Dulin N., Zvartau N., Kolenko V.M. Zinc inhibits nuclear factor κB activation and sensitizes prostate cancer cytotoxic agents. Clin. Cancer Res. 8:2002;3579-3583
18. Choi D.W., Koh J.Y. Zinc and brain injury. Annu. Rev. Neurosci. 21:1998;347-375
19. Suh S.W., Chen J.W., Motamedi M., Bell B., Listiak K., Pons N.F., Danscher G., Frederickson C.J. Evidence that synaptically-released zinc contributes to neuronal injury after traumatic brain injury. Brain Res. 852:2000;268-273
20. Lee J.M., Zipfel G.J., Park K.H., He Y.Y., Hsu C.Y., Choi D.W. Zinc translocation accelerates infarction after mild transient focal ischemia. Neuroscience. 115:2002;871-878
21. Danscher G., Jensen K.B., Frederickson C.J., Kemp K., Andreasen A., Juhl S., Stoltenberg M., Ravid R. Increased amount of zinc in the hippocampus and amygdala of Alzheimer's diseased brains: a proton-induced X-ray emission spectroscopic analysis of cryostat sections from autopsy material. J. Neurosci. Methods. 76:1997;53-59
22. Suh S.W., Jensen K.B., Jensen M.S., Silva D.S., Kesslak P.J., Danscher G., Frederickson C.J. Histochemically-reactive zinc in amyloid plaques, angiopathy, and degenerating neurons of Alzheimer's disease brains. Brain Res. 852:2000;274-278
23. Bush A.I., Tanzi R.E. The galvanization of β-amyloid in Alzheimer's disease. Proc. Natl. Acad. Sci. U. S. A. 99:2002;7317-7319
24. Glickman M.H., Ciechanover A. The ubiquitin-proteasome proteolytic pathway: destruction for the sake of construction. Physiol. Rev. 82:2001;373-428
25. Laney J., Hochstrasser M. Substrate targeting in the ubiquitin system. Cell. 97:1997;427-430
26. Chang Y., Lee Y., Tejima T., Tanaka K., Omura S., Heintz N.H., Mitsui Y., Magae J. mdm2 and bax, downstream mediators of the p53 response, are degraded by the ubiquitin-proteasome pathway. Cell Growth Differ. 9:1998;79-84
27. Ciechanover A. The ubiquitin-proteasome pathway: on protein death and cell life. EMBO J. 17:1998;7151-7160
28. Adams J., Palombella V.J., Sausville E.A., Johnson J., Destree A., Lazarus D.D., Maas J., Pien C.S., Prakash S., Elliott P.J. Proteasome inhibitors: a novel class of potent and effective anti-tumor agents. Cancer Res. 59:1999;2615-2622
29. Jesenberger V., Jentsch S. Deadly encounter: ubiquitin meets apoptosis. Nat. Rev., Mol. Cell Biol. 3:2002;112-121
30. Tsurumi C., Ishida N., Tamura T., Kakizuka A., Nishida E., Okumura E., Kishimoto T., Inagaki M., Okazaki K., Sagata N., Ichihara A., Tanaka K. Degradation of c-Fos by the 26S proteasome is accelerated by c-Jun and multiple protein kinases. Mol. Cell. Biol. 15:1995;5682-5687
31. Kallio P.J., Wilson W.J., O'Brien S., Makino Y., Peollinger L. Regulation of the hypoxia-inducible transcription factor 1α by the ubiquitin-proteasome pathway. J. Biol. Chem. 274:1999;6519-6525
32. Stancovski I., Gonen H., Orian A., Schwartz A.L., Ciechanover A. Degradation of the proto-oncogene product c-Fos by the ubiquitin proteolytic system in vivo and in vitro: identification and characterization of the conjugating enzymes. Mol. Cell. Biol. 15:1995;7106-7116
33. Hungness E.S., Robb B.W., Luo G., Pritts T.A., Hershko D.D., Hasselgren P. Proteasome inhibitors activate the transcription factors C/EBP-β and δ in human intestinal epithelial cells. Biochem. Biophys. Res. Commun. 290:2002;469-474
34. Palombella V.J., Rando O.J., Goldberg A.L., Maniatis T. The ubiquitin-proteasome pathway is required for processing the NF-κB1 precursor protein and the activation of NF-κB. Cell. 78:1994;773-785
35. Traenckner E.B., Wilk S., Baeuerle P.A. A proteasome inhibitor prevents activation of NF-κB and stabilizes a newly phosphorylated form of IκB-α that is still bound to NF-κB. EMBO J. 15:1994;5433-5441
36. Park J.A., Koh J.Y. Induction of an immediate early gene egr-1 by zinc through extracellular signal-regulated kinase activation in cortical culture: its role in zinc-induced neuronal death. J. Neurochem. 73:1999;450-456
37. WAF1/CIP1 expression. Biochem. Biophys. Res. Commun. 227:1996;564-569
38. Maki C.G., Huibregtse J.M., Howley P.M. In vivo ubiquitination and proteasome-mediated degradation of p53. Cancer Res. 56:1996;2649-2654
39. Kubbutat M.H.G., Vousden K.H. Proteolytic cleavage of human p53 by calpain: a potential regulator of protein stability. Mol. Cell. Biol. 17:1997;460-468
40. Lee D.H., Goldberg A.L. Proteasome inhibitors: valuable new tools for cell biologists. Trends Cell Biol. 8:1998;397-403
41. Dantuma N.P., Lindsten K., Glas R., Jellne M., Masucci M.G. Short-lived green fluorescent proteins for quantifying ubiquitin/proteasome-dependent proteolysis in living cells. Nat. Biotechnol. 18:2000;538-543
42. Wigley W.C., Fabunmi R.P., Lee M.G., Marino C.R., Muallem S., DeMartino G.N., Thomas P.J. Dynamic association of proteasomal machinery with the centrosome. J. Cell Biol. 145:1999;481-490
43. Hirsch C., Ploegh H.L. Intracellular targeting of the proteasome. Trends Cell Biol. 10:2000;268-272
44. Nothwang H.G., Coux O., Bey F., Scherrer K. Disruption of prosomes by some bivalent metal ions results in the loss of their multicatalytic proteinase activity and cancels the nuclease resistance of prosomal RNA. Biochem. J. 287:1992;733-739
45. Amici M., Forti K., Nobili C., Lupidi G., Angeletti M., Fioretti E., Eleuteri A.M. Effect of neurotoxic metal ions on the proteolytic activities of the 20S proteasome from bovine brain. J. Biol. Inorg. Chem. 7:2002;750-756
46. Cip1 ubiquitination. Mol. Cell. 5:2000;403-410
47. Liu C., Corboy M.J., DeMartino G.N., Thomas P.J. Endoproteolytic activity of the proteasome. Science. 299:2003;408-411
48. Johnston J.A., Ward C.L., Kopito R.R. Aggresomes: a cellular response to misfoled proteins. J. Cell Biol. 143:1998;1883-1898
49. Gabriel J.M., Lacombe T., Carobbio S., Paquet N., Bisig R., Cox J.A., Jaton J.C. Zinc is required for the catalytic activity of the human deubiquitinating isopeptidase T. Biochemistry. 41:2002;13755-13766
50. Bloom J., Amador V., Bartolini F., DeMartino G., Pagano M. Proteasome-mediated degradation of p21 via N-terminal ubiquitinylation. Cell. 115:2003;71-82
51. Shim M., Smart R.C. Lithium stabilizes the CCAAT/Enhancer-binding protein α (C/EBPα) through a glycogen synthase kinase 3 (GSK3)-independent pathway involving direct inhibition of proteasomal activity. J. Biol. Chem. 278:2003;19674-19681
52. Stewart D., Killeen E., Naquin R., Alam S., Alam J. Degradation of transcription factor Nrf2 via the ubiquitin-proteasome pathway and stabilization by cadmium. J. Biol. Chem. 278:2003;2396-2402
53. Koh J.Y., Suh S.W., Gwag B.J., He Y.Y., Hsu C.Y., Choi D.W. The role of zinc in selective neuronal death after transient global cerebral ischemia. Science. 272:1996;1013-1016
54. Cherny R.A., Atwood C.S., Xilinas M.E., Gray D.N., Jones W.D., McLean C.A., Barnham K.J., Volitakis I., Fraser F.W., Kim Y., Huang X., Goldstein L.E., Moir R.D., Lim J.T., Beyreuther K., Zheng H., Tanzi R.E., Masters C.L., Bush A.I. Treatment with a copper-zinc chelator markedly and rapidly inhibits β-amyloid accumulation in Alzheimer's disease transgenic mice. Neuron. 30:2001;665-676
55. Honda T., Yasutake K., Nihonmatsu N., Mercken M., Takahashi H., Murayama O., Murayama M., Sato K., Omori A., Tsubuki S., Saido T.C., Takashima A. Dual roles of proteasome in the metabolism of presenilin-1. J. Neurochem. 72:1999;255-261
56. Hyun D.H., Lee M.H., Halliwell B., Jenner P. Proteasome dysfunction induced by 4-hydroxy-2, 3-trans-nonenal, an end-product of lipid peroxidation: a mechanism contributing to neurodegeneration. J. Neurochem. 83:2002;360-370
57. Keck S., Nitsch R., Grune T., Ullrich O. Proteasome inhibition by paired helical filament-tau in brains of patients with Alzheimer's disease. J. Neurochem. 85:2003;115-122
58. Keller J.N., Hanni K.B., Markesbery W.R. Impaired proteasome function in Alzheimer's disease. J. Neurochem. 75:2000;436-439
59. McNaught K.St.P., Jenner P. Proteasomal function is impaired in substantia nigra in Parkinson's disease. Neurosci. Lett. 297:2001;191-194